Skip to main content
Erschienen in: Annals of Nuclear Medicine 8/2016

05.07.2016 | Original Article

Impact of patient age on the iodine/FDG “flip-flop” phenomenon in lung metastasis from thyroid cancer

verfasst von: Takuro Isoda, Shingo BaBa, Yasuhiro Maruoka, Yoshiyuki Kitamura, Keiichiro Tahara, Masayuki Sasaki, Hiroshi Honda

Erschienen in: Annals of Nuclear Medicine | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Radioiodine therapy is an effective treatment for lung metastasis from thyroid cancer. However, cases of lung metastasis without iodine uptake are often encountered. In such cases, FDG accumulation in lung lesions is often observed. There is a reverse relationship between iodine and FDG accumulation in thyroid cancer lesions, the so-called “flip-flop” phenomenon. The aim of this study was to assess the relationship between patient age and the occurrence of the flip-flop phenomenon.

Methods

Eighty-six patients who underwent radioiodine therapy for lung metastasis were studied retrospectively (age 17–73 years; median 60 years; males:females 22:64). We compared the clinical data and imaging findings (size and FDG uptake of lung nodules) between patients with (n = 44) and without (n = 42) iodine uptake in lung metastasis.

Results

Significantly more young patients showed iodine accumulation in lung metastasis than old patients (p = 0.0025). Lung metastases with larger size or greater FDG uptake showed no iodine uptake more frequently with significant difference (p = 0.015 and <0.001, respectively). Among patients with FDG uptake in the lung metastasis, 57.1 % of young patients (<60 years) and 24.3 % of the old patients (≥60 years) showed iodine uptake (p = 0.0029).

Conclusions

Higher patient age and lung nodules with large size or FDG accumulation are negative factors for iodine accumulation in lung metastases from thyroid cancer. In addition, our results show that young patients have a greater likelihood of iodine uptake even when FDG accumulates in lung metastasis, in contrast to old patients.
Literatur
1.
Zurück zum Zitat Robbins RJ, Schlumberger MJ. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med. 2005;46(Suppl 1):28S–37S.PubMed Robbins RJ, Schlumberger MJ. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med. 2005;46(Suppl 1):28S–37S.PubMed
2.
Zurück zum Zitat Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941–59.CrossRefPubMed Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941–59.CrossRefPubMed
3.
Zurück zum Zitat Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.CrossRefPubMed Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.CrossRefPubMed
4.
Zurück zum Zitat Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer. 1998;82:375–88.CrossRefPubMed Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer. 1998;82:375–88.CrossRefPubMed
5.
Zurück zum Zitat Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer. 1985;55:794–804.CrossRefPubMed Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer. 1985;55:794–804.CrossRefPubMed
6.
Zurück zum Zitat Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med. 1996;37:598–605.PubMed Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med. 1996;37:598–605.PubMed
7.
Zurück zum Zitat Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Brennan MF, et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg. 2003;197:191–7.CrossRefPubMed Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Brennan MF, et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg. 2003;197:191–7.CrossRefPubMed
8.
Zurück zum Zitat Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab. 1995;80:2041–5.PubMed Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab. 1995;80:2041–5.PubMed
9.
Zurück zum Zitat Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1986;63:960–7.CrossRefPubMed Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1986;63:960–7.CrossRefPubMed
10.
Zurück zum Zitat Pak K, Kim SJ, Kim IJ, Kim BH, Kim SS, Jeon YK. The role of 18F-fluorodeoxyglucose positron emission tomography in differentiated thyroid cancer before surgery. Endocr Relat Cancer. 2013;20:R203–13.CrossRefPubMed Pak K, Kim SJ, Kim IJ, Kim BH, Kim SS, Jeon YK. The role of 18F-fluorodeoxyglucose positron emission tomography in differentiated thyroid cancer before surgery. Endocr Relat Cancer. 2013;20:R203–13.CrossRefPubMed
11.
Zurück zum Zitat Kohlfurst S. The role of nuclear medicine in differentiated thyroid cancer. Wien Med Wochenschr. 2012;162:407–15.CrossRefPubMed Kohlfurst S. The role of nuclear medicine in differentiated thyroid cancer. Wien Med Wochenschr. 2012;162:407–15.CrossRefPubMed
12.
Zurück zum Zitat Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, et al. [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291–302.CrossRefPubMed Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, et al. [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291–302.CrossRefPubMed
13.
Zurück zum Zitat Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med. 2006;47:616–24.PubMed Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med. 2006;47:616–24.PubMed
14.
Zurück zum Zitat Kaneko K, Abe K, Baba S, Isoda T, Yabuuchi H, Sasaki M, et al. Detection of residual lymph node metastases in high-risk papillary thyroid cancer patients receiving adjuvant I-131 therapy: the usefulness of F-18 FDG PET/CT. Clin Nucl Med. 2010;35:6–11.CrossRefPubMed Kaneko K, Abe K, Baba S, Isoda T, Yabuuchi H, Sasaki M, et al. Detection of residual lymph node metastases in high-risk papillary thyroid cancer patients receiving adjuvant I-131 therapy: the usefulness of F-18 FDG PET/CT. Clin Nucl Med. 2010;35:6–11.CrossRefPubMed
15.
Zurück zum Zitat Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996;37:1468–72.PubMed Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996;37:1468–72.PubMed
16.
Zurück zum Zitat Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–9.CrossRefPubMed Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–9.CrossRefPubMed
17.
Zurück zum Zitat Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–28.CrossRefPubMed Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–28.CrossRefPubMed
18.
Zurück zum Zitat Nagamachi S, Wakamatsu H, Kiyohara S, Nishii R, Mizutani Y, Fujita S, et al. Comparison of diagnostic and prognostic capabilities of (1)(8)F-FDG-PET/CT, (1)(3)(1)I-scintigraphy, and diffusion-weighted magnetic resonance imaging for postoperative thyroid cancer. Jpn J Radiol. 2011;29:413–22.CrossRefPubMed Nagamachi S, Wakamatsu H, Kiyohara S, Nishii R, Mizutani Y, Fujita S, et al. Comparison of diagnostic and prognostic capabilities of (1)(8)F-FDG-PET/CT, (1)(3)(1)I-scintigraphy, and diffusion-weighted magnetic resonance imaging for postoperative thyroid cancer. Jpn J Radiol. 2011;29:413–22.CrossRefPubMed
19.
Zurück zum Zitat La Quaglia MP, Black T, Holcomb GW 3rd, Sklar C, Azizkhan RG, Haase GM, et al. Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children’s Cancer Group. J Pediatr Surg. 2000;35:955–9 (discussion 960).CrossRefPubMed La Quaglia MP, Black T, Holcomb GW 3rd, Sklar C, Azizkhan RG, Haase GM, et al. Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children’s Cancer Group. J Pediatr Surg. 2000;35:955–9 (discussion 960).CrossRefPubMed
20.
Zurück zum Zitat Francis Z, Schlumberger M. Serum thyroglobulin determination in thyroid cancer patients. Best Pract Res Clin Endocrinol Metab. 2008;22:1039–46.CrossRefPubMed Francis Z, Schlumberger M. Serum thyroglobulin determination in thyroid cancer patients. Best Pract Res Clin Endocrinol Metab. 2008;22:1039–46.CrossRefPubMed
21.
Zurück zum Zitat Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2002;43:1188–200.PubMed Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2002;43:1188–200.PubMed
22.
Zurück zum Zitat Haymart MR. Understanding the relationship between age and thyroid cancer. Oncologist. 2009;14:216–21.CrossRefPubMed Haymart MR. Understanding the relationship between age and thyroid cancer. Oncologist. 2009;14:216–21.CrossRefPubMed
23.
Zurück zum Zitat Jarzab B, Handkiewicz-Junak D, Wloch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer. 2005;12:773–803.CrossRefPubMed Jarzab B, Handkiewicz-Junak D, Wloch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer. 2005;12:773–803.CrossRefPubMed
Metadaten
Titel
Impact of patient age on the iodine/FDG “flip-flop” phenomenon in lung metastasis from thyroid cancer
verfasst von
Takuro Isoda
Shingo BaBa
Yasuhiro Maruoka
Yoshiyuki Kitamura
Keiichiro Tahara
Masayuki Sasaki
Hiroshi Honda
Publikationsdatum
05.07.2016
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 8/2016
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-016-1104-9

Weitere Artikel der Ausgabe 8/2016

Annals of Nuclear Medicine 8/2016 Zur Ausgabe